TScan Therapeutics (TCRX) Total Liabilities (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Total Liabilities of $105.1 million for Q1 2026, down 14.23% year-over-year from $122.5 million in Q1 2025, and down 0.56% quarter-over-quarter from $105.7 million in Q4 2025.
TScan Therapeutics (TCRX) Total Liabilities (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Total Liabilities for 7 consecutive years, with $105.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 14.23% year-over-year to $105.1 million; the TTM figure through Mar 2026 stood at $105.1 million (down 14.23% YoY), while the FY2025 annual figure was $105.7 million, down 18.81% from the prior year.
- Total Liabilities fell to $105.1 million in Q1 2026 per TCRX's latest filing, from $105.7 million in the prior quarter.
- Across five years, Total Liabilities topped out at $130.1 million in Q4 2024 and bottomed at $20.8 million in Q2 2022.
- Historically, Total Liabilities has averaged $101.0 million across 5 years, with a median of $118.2 million in 2025.
- Annual changes were most pronounced in 2022 — Total Liabilities plunged 32.2% — and 2023, when it soared 508.37%.
- TScan Therapeutics' Total Liabilities stood at $99.7 million in 2022, then gained by 21.7% to $121.3 million in 2023, then advanced by 7.31% to $130.1 million in 2024, then slipped by 18.81% to $105.7 million in 2025, then dropped by 0.56% to $105.1 million in 2026.
- Business Quant data shows TCRX's Total Liabilities at $105.1 million in Q1 2026, $105.7 million in Q4 2025, and $118.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 102.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.43 Mn |
| Mar 31, 2026 | 105.07 Mn |
| Dec 31, 2025 | 105.67 Mn |
| Sep 30, 2025 | 118.20 Mn |
| Jun 30, 2025 | 121.85 Mn |
| Mar 31, 2025 | 122.51 Mn |
| Dec 31, 2024 | 130.15 Mn |
| Sep 30, 2024 | 118.94 Mn |
| Jun 30, 2024 | 119.65 Mn |
| Mar 31, 2024 | 117.87 Mn |
| Dec 31, 2023 | 121.28 Mn |
| Sep 30, 2023 | 122.42 Mn |
| Jun 30, 2023 | 126.32 Mn |
| Mar 31, 2023 | 95.56 Mn |
| Dec 31, 2022 | 99.66 Mn |
| Sep 30, 2022 | 48.80 Mn |
| Jun 30, 2022 | 20.76 Mn |
| Mar 31, 2022 | 22.51 Mn |
| Dec 31, 2021 | 27.33 Mn |
| Sep 30, 2021 | 30.82 Mn |